<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="61894">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01670136</url>
  </required_header>
  <id_info>
    <org_study_id>11-1646</org_study_id>
    <nct_id>NCT01670136</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of Sildenafil in Premature Infants</brief_title>
  <official_title>Pharmacokinetics of Sildenafil in Premature Infants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of North Carolina, Chapel Hill</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>The EMMES Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of North Carolina, Chapel Hill</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to learn more about the safety and dosing of sildenafil in
      infants.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pharmacokinetics and safety of sildenafil will be studied in preterm infants who are
      receiving sildenafil per standard of care or 1 dose prescribed for the study.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Anticipated">May 2015</completion_date>
  <primary_completion_date type="Anticipated">November 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>Area under the plasma concentration versus time curve 0-24 hours for sildenafil</measure>
    <time_frame>IV study dose 0-15 min,1-2,3-4,12-14,24-30,48-56hr after flush.Clinical care: IV &lt;0.5hr before dose &lt;15 min &amp; 3-4hr after flush &lt;0.5hr before next dose. Enteral &lt;0.5hr before dose, 1-2 &amp; 3-4hr after dose, &lt;0.5hr before next dose.  22-26hr after last dose</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Peak plasma concentration of sildenafil</measure>
    <time_frame>IV study dose 0-15 min,1-2,3-4,12-14,24-30,48-56hr after flush.Clinical care: IV &lt;0.5hr before dose &lt;15 min &amp; 3-4hr after flush &lt;0.5hr before next dose. Enteral &lt;0.5hr before dose, 1-2 &amp; 3-4hr after dose, &lt;0.5hr before next dose. 22-26hr after last dose</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Clearance of sildenafil</measure>
    <time_frame>IV study dose 0-15 min,1-2,3-4,12-14,24-30,48-56hr after flush.Clinical care: IV &lt;0.5hr before dose &lt;15 min &amp; 3-4hr after flush &lt;0.5hr before next dose. Enteral &lt;0.5hr before dose, 1-2 &amp; 3-4hr after dose, &lt;0.5hr before next dose. 22-26hr after last dose</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Volume of distribution at steady state</measure>
    <time_frame>IV study dose 0-15 min,1-2,3-4,12-14,24-30,48-56hr after flush.Clinical care: IV &lt;0.5hr before dose &lt;15 min &amp; 3-4hr after flush &lt;0.5hr before next dose. Enteral &lt;0.5hr before dose, 1-2 &amp; 3-4hr after dose, &lt;0.5hr before next dose. 22-26hr after last dose</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Half life of sildenafil</measure>
    <time_frame>IV study dose 0-15 min,1-2,3-4,12-14,24-30,48-56hr after flush.Clinical care: IV &lt;0.5hr before dose &lt;15 min &amp; 3-4hr after flush &lt;0.5hr before next dose. Enteral &lt;0.5hr before dose, 1-2 &amp; 3-4hr after dose, &lt;0.5hr before next dose. 22-26hr after last dose</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with adverse events as a measure of safety and tolerability.</measure>
    <time_frame>From the time of the first dose to 3 days after the last dose; serious adverse events will be collected from the first dose of sildenafil to 7 days after the last dose of sildenafil</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between serum and dried blood spot samples</measure>
    <time_frame>1-7 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate P450 single nucleotide polymorphisms (SNPs)</measure>
    <time_frame>2-7 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">41</enrollment>
  <condition>Persistent Pulmonary Hypertension of the Newborn</condition>
  <arm_group>
    <arm_group_label>sildenafil, standard of care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Infants receiving sildenafil as standard of care</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sildenafil administered for study</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>1 dose of sildenafil administered for study</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1 dose of sildenafil</intervention_name>
    <description>A single IV dose of sildenafil will be administered over 90 minutes with no greater than a 15-minute flush.  Final dose to be determined based on at least the first 4 participants enrolled in Cohort 1; final dose expected to be a single dose between 0.25 and 0.75 mg/kg.</description>
    <arm_group_label>sildenafil administered for study</arm_group_label>
    <other_name>Revatio</other_name>
    <other_name>Viagra</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Cohort 1:

          -  Gestational age 28 weeks or less receiving sildenafil as standard of care &lt; 365
             postnatal days

        Cohort 2:

          -  Gestational age 28 weeks or less

          -  7-28 postnatal days of age

          -  Mechanical ventilation or nasal continuous positive airway pressure (NCPAP) or
             high-flow nasal cannula

          -  Intravenous line in place

        Exclusion Criteria:

        Cohort 1:

          -  Any condition that would make the participant, in the opinion of the investigator,
             unsuitable for the study

        Cohort 2:

          -  Previous exposure to sildenafil within 7 days prior to enrollment

          -  Any condition that would make the participant, in the opinion of the investigator,
             unsuitable for the study

          -  History of allergic reactions to sildenafil

          -  AST &gt; ULN or ALT &gt; 3x ULN

          -  Currently on a vasopressor for hypotension

          -  Known sickle cell disease
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>364 Days</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthew M Laughon, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of North Carolina</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Matthew M Laughon, MD, MPH</last_name>
    <phone>919-966-5063</phone>
    <email>matt_laughon@med.unc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Maurine Morris</last_name>
    <phone>919-668-8349</phone>
    <email>maurine.morris@duke.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35249-7335</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ambalavanan Namasivayam, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Riley Hospital</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Shawn Ahlfeld, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kosair Pediatric Research Unit</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Dan Stewart, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of North Carolina</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Sigal Peter-Wohl, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>C. Michael Cotten, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Andrew Atz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 5, 2014</lastchanged_date>
  <firstreceived_date>August 17, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>sildenafil</keyword>
  <keyword>preterm infants</keyword>
  <keyword>persistent pulmonary hypertension of the newborn</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Hypertension, Pulmonary</mesh_term>
    <mesh_term>Persistent Fetal Circulation Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Sildenafil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
